Skip to main content

Helicos Seeks to Raise $6.4M in Direct Offering

NEW YORK (GenomeWeb News) – Helicos BioSciences said after the close of the market yesterday that it has priced a registered direct offering of 6.4 million units at $1 per unit, which would provide the firm with $6.4 million in gross proceeds.

Each unit in the offering consists of one share of Helicos common stock and a warrant to buy .65 of a share of common stock. The warrants are exercisable for a period of five years beginning six months after issuance, at an exercise price of $1.4385 per share.

Helicos expects to close the offering on or around Dec. 21.

The firm plans to use the proceeds for its ongoing research and development efforts and general corporate purposes.

Helicos filed a registration statement with the US Securities and Exchange Commission in early November, in which it said that it may offer up to $50 million worth of its common stock and/or warrants to purchase common stock in one or more transactions.

In early Wednesday trade on the Nasdaq, shares of Helicos tumbled 30 percent to $.96.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.